Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 11/27/2025

Testosterone Replacement Therapy Guidelines

Initial Dosing Regimens

  • The American College of Physicians recommends initiating testosterone cypionate or enanthate 100-200 mg intramuscularly every 2 weeks, or preferably 50-100 mg weekly for more stable levels, targeting mid-normal testosterone levels of 500-600 ng/dL 1
  • Weekly dosing of 50-100 mg is increasingly favored because it reduces problematic peaks and troughs, providing more stable testosterone levels throughout the dosing interval 2
  • Testosterone gel 1-2%: 50-100 mg applied daily to the skin of the back, abdomen, upper thighs, or upper arms 1
  • Transdermal preparations produce less fluctuation in testosterone levels compared to injections and carry lower risk of erythrocytosis 3

Target Testosterone Levels

  • Aim for mid-normal range (450-600 ng/dL) rather than upper normal limits to optimize response while minimizing adverse effects 3
  • For patients receiving injections, measure testosterone levels midway between injections (at trough) 2-3 months after initiation, targeting mid-normal values of 500-600 ng/dL 1, 2
  • Do not dose based on peak levels—patients measured shortly after injection may appear adequate but spend most of the interval in subtherapeutic ranges 2

Monitoring and Dose Adjustment

  • First follow-up visit at 1-2 months to assess efficacy and consider dose escalation if inadequate clinical response with suboptimal testosterone levels 4
  • Subsequent visits at 3-6 month intervals for the first year, then yearly thereafter 4
  • If clinical response is suboptimal and testosterone levels remain in the low-normal range, increase the testosterone dosage 4
  • If maximal transdermal dose fails to achieve adequate levels, switch to intramuscular therapy 4
  • Reevaluate symptoms within 12 months and discontinue if no improvement in target symptoms 5, 6

Critical Safety Monitoring

  • Measure PSA and hematocrit/hemoglobin levels 4
  • Perform digital rectal examination 4
  • Assess voiding symptoms and any history of sleep apnea 4
  • Monitor hematocrit closely—if it rises above 54%, this represents a medical urgency requiring immediate intervention with temporary discontinuation or therapeutic phlebotomy 3
  • Measure serum testosterone, PSA levels, and hematocrit 4
  • Assess symptomatic response, voiding symptoms, and cardiovascular symptoms 4, 3

Important Clinical Considerations

  • Standard testosterone esters produce an initial peak within 2-7 days, followed by progressive decline to subtherapeutic levels by days 13-14 2
  • Patients spend significant time in both supratherapeutic and subtherapeutic ranges between injections, which may contribute to increased cardiovascular risk 2
  • Intramuscular formulations are preferred over transdermal when initiating therapy because costs are considerably lower and clinical effectiveness and harms are similar 5, 6
  • However, injectable testosterone is associated with substantially higher rates of erythrocytosis compared to transdermal preparations 3
  • Never treat to raise levels above the physiologic range, although recognize that peak levels transiently rise above normal with standard injection dosages 4
  • If adequate clinical response occurs, no dosage adjustment is needed even if levels are in the low-normal range 4
  • For injection therapy, interpret blood test results based on interval since last injection—peak levels occur 2-5 days post-injection and often return to baseline by 10-14 days 4